Non-dilutive funding Leverage AVM Biotechnology's recent $2M plus additional $2M NCI SBIR grants (total government funding of $6.4M) to position partnerships around grant-aligned development programs, co-funding opportunities, and milestone-driven collaborations with larger biopharma.

Immuno-oncology niche Target oncology developers seeking novel immune mobilization strategies by offering collaborative programs around AVM0703’s mechanism to mobilize endogenous gamma delta TCR+ and invariant TCR+ bispecific NK-like cells for NHL and solid tumors.

Clinical-stage partnerships Capitalize on AVM’s clinical-stage status and strong scientific advisory board to pursue licensing, co-development, or strategic alliance discussions with mid-to-large biotechs seeking differentiated immunotherapy assets with potentially lower systemic toxicity.

Executive alignment Engage with AVM’s leadership team additions in commercial and financial leadership to explore early commercial pathway planning, market access strategy, and tailored deal structures for a potential near-term launch.

Strategic expansion Propose joint development or regional partnership opportunities that align AVM0703's potential applications in cancer, autoimmunity, and infectious disease with partner pipelines, enabling diversification across indications and geographies.